

AMENDMENTS TO THE CLAIMS

1. (Withdrawn; Currently Amended) ~~A peptide~~ An isolated peptide selected from the group of peptides consisting of the amino acid sequence given in SEQ ID NO: 1 to SEQ ID NO: 7 wherein said peptide can induce a cytotoxic CTL targeting to a HIV infected cell.

2. (Currently Amended) ~~A DNA~~ An isolated DNA molecule coding for a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

3. (Withdrawn) A medicament for preventing and/or treating of AIDS, comprising the peptide of claim 1, a pharmaceutically acceptable carrier and/or a diluent.

4. (Previously Presented) The DNA molecule of Claim 2, wherein said DNA molecule codes for a peptide having an amino acid sequence of SEQ ID NO: 4.

5. (Withdrawn) The DNA molecule of Claim 4, wherein the codon usage of the DNA molecule is optimized for the cell used for expression of said DNA molecule.

6. (Withdrawn) A host cell comprising the DNA molecule of Claim 5.

7. (Withdrawn) A host cell comprising the DNA molecule of Claim 4.

8. (Withdrawn) An expression vector comprising the DNA molecule of Claim 4.

9. (Withdrawn) A complementary DNA molecule that hybridizes with the DNA molecule of Claim 4 under stringent conditions.

10. (Withdrawn) The complementary DNA molecule of Claim 9, wherein said stringent conditions comprise:

annealing at 20-25°C below the melting temperature, T_m , in 2 x SSC, wherein T_m is determined by the equation:

$$(T_m = 81.5^{\circ}\text{C} + \log_{10}[\text{Na}^+] + 0.41(\text{G+C content \%}) - (600/\text{sequence length})),$$

and washing at 12-20°C below the T_m with a salt concentration of 0.1 x SSC.

11. (Withdrawn) A method of inducing cytotoxic CTL targeting to a HIV infected cell comprising:

expressing the DNA molecule of Claim 4 in a host cell to produce a peptide of SEQ ID NO: 4;

obtaining said peptide of SEQ ID NO: 4;

administering said peptide of SEQ ID NO: 4 to a subject in need thereof.

12. (Withdrawn) The method of Claim 11, wherein said administering comprises a method selected from the group consisting of injection, aerosol, and transdermal application.

SUPPORT FOR THE AMENDMENT

Claims 1 and 2 have been amended.

The amendment of Claims 1 and 2 is supported by page 6, line 25 to page 10, line 5 of the specification as originally filed.

No new matter has been added by the present amendment.